In contrast to the results of a number of RCTs showing no improvement in HbA1c with the use of flash glucose monitoring in T2D36, a RCT by Beck et al involving 158 adults with insulin-treated T2D using CGM technology over 24 weeks showed increased time in range and a reduction in HbA1c of at least 0.5% in 73% of the CGM group, compared to 49% of control group (adjusted difference in mean change in HbA1c from baseline -0.3% (CI -0.5% to 0.0%) p=0.022). The gene discussed is INS; the disease is type 2 diabetes mellitus.